5243722025-04-012025-06-305243722025-04-012025-06-30in-capmkt:OtherExpenses1Member5243722025-04-012025-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

524372

ORCHPHARMA

NOTLISTED

INE191A01027

Orchid Pharma Limited

Main Board

Equity

2025-04-01

2026-03-31

2025-08-12

2025-08-05

INR

Lakhs

Quarterly

First quarter

Single segment

Pharmaceuticals

2025-08-12

12:00:00

2025-08-12

15:30:00

Not applicable

2025-04-01

2025-06-30

Unaudited

Consolidated

1729288000

114476000

1843764000

1101574000

7879000

-120799000

216129000

32575000

86541000

382753000

1706652000

137112000

11994000

149106000

-1548000

147558000

507191000

2.94

1. The above results for the quarter and year ended June 30 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 12, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. 2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. 3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. As on June 30, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : Statement of QIP Net Funds raised and utilisation Particulars Amount as stated in Total amount utilised Balance amount as on Remarks the Offer Document upto June 30, 2025 on June 30, 2025 kept Rs. In Lakhs Rs. In Lakhs in Fixed Deposits Rs.in lakhs 1. Investment in OBPL, subsidiary, for setting up Jammu Manufacturing Facility 9000 6461 2539 2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company 14100 14100 - 3. Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu 9982 36 9946 4. General corporate purposes 6098 6372 0 Total 39180 26969 12485 As per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on June 30, 2025. Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. 4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. 5. The figures for the quarters ended 31 March, 2025 represents the balancing figures between audited results for the year ended March 31, 2025 and the published year to date figures up to the third quarter of the relevant year. 6. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the Company in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, giving No objection to the said amalgamation. The Honourable NCLT vide its order dated 29th April, 2025 , inter alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed with the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Honourable NCLT. Subsequently, the requisite approvals of the concerned shareholders and creditors, as directed, have duly been secured. Further the companies submitted the joint company petition seeking approval on the scheme of Amalgamation, pursuant to which the Honourable NCLT admitted the petion for its consideration and sanction. 7. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary.

Other expenses

382753000

Items that will not be reclassified to Profit and loss

-1548000